title: Treatment of hyperprolactinemia in post-menopausal women: pros.
abstract: The incidence of hyperprolactinemia in women peaks during the 3rd-4th decade and then greatly decreases after the menopause. Apart from the effects on the hypothalamic-pituitary-gonadal axis, prolactin can act directly on bone metabolism. Hyperprolactinemia is a recognized cause of secondary osteoporosis, and treatment with dopamine agonists can lead to improved BMD. Moreover, hyperprolactinemia has been linked to weight gain and insulin resistance, which can be ameliorated following medical treatment. Although relatively rare, prolactinomas can be observed in post-menopausal women and are frequently large and invasive; dopamine agonists appear to be as effective in these patients as in younger women to induce reduction of prolactin levels and tumour shrinkage. Here, we review data potentially favouring medical treatment with dopamine agonists in post-menopausal women diagnosed with hyperprolactinemia.
authors.affiliation: Endocrinology, Università Cattolica del Sacro Cuore, Policlinico "A. Gemelli", Rome, Italy, donatoiacovazzo@gmail.com.
authors.forename: D
authors.initials: D
authors.lastname: Iacovazzo
authors.forename: L
authors.initials: L
authors.lastname: De Marinis
mesh_terms: D000328:Adult; D000368:Aged; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000150:complications / Q000628:therapy; D017698:Postmenopause / Q000378:metabolism*; D015175:Prolactinoma / Q000150:complications / Q000628:therapy
references.citation: J Clin Endocrinol Metab. 2003 Apr;88(4):1804-8
references.pmid: 12679477
references.citation: Clin Endocrinol (Oxf). 2001 Mar;54(3):295-300
references.pmid: 11298080
references.citation: Eur J Endocrinol. 2002 Jul;147(1):77-84
references.pmid: 12088923
references.citation: Pituitary. 2011 Sep;14(3):259-65
references.pmid: 21221817
references.citation: Endocrine. 2011 Jun;39(3):288-93
references.pmid: 21479837
references.citation: J Clin Endocrinol Metab. 2011 Feb;96(2):273-88
references.pmid: 21296991
references.citation: Clin Endocrinol (Oxf). 1998 May;48(5):547-53
references.pmid: 9666865
references.citation: Endocrine. 2014 Dec;47(3):889-94
references.pmid: 24711223
references.citation: Nat Rev Endocrinol. 2011 May;7(5):254-5
references.pmid: 21326279
references.citation: J Cell Biochem. 2009 Jul 1;107(4):677-85
references.pmid: 19365811
references.citation: Mol Cell Endocrinol. 1982 Mar;25(3):277-94
references.pmid: 7067928
references.citation: J Clin Endocrinol Metab. 1987 May;64(5):1021-6
references.pmid: 3558723
references.citation: Bone. 2008 Mar;42(3):535-46
references.pmid: 18166509
references.citation: N Engl J Med. 1986 Aug 28;315(9):542-6
references.pmid: 3736637
references.citation: J Clin Endocrinol Metab. 2009 Aug;94(8):2729-34
references.pmid: 19491225
references.citation: J Clin Endocrinol Metab. 2000 Jun;85(6):2247-52
references.pmid: 10852458
references.citation: Eur J Endocrinol. 2012 Nov;167(5):651-62
references.pmid: 22918301
references.citation: Pituitary. 2011 Dec;14(4):299-306
references.pmid: 21301967
references.citation: Pituitary. 2009;12(2):96-104
references.pmid: 18338266
references.citation: Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73
references.pmid: 16886971
references.citation: Eur J Endocrinol. 2013 Nov 22;170(1):31-8
references.pmid: 24088550
references.citation: Endocrine. 2013 Aug;44(1):193-9
references.pmid: 23233277
references.citation: J Endocrinol Invest. 2003 Apr;26(4):341-6
references.pmid: 12841542
references.citation: Endocrinol Metab Clin North Am. 2008 Mar;37(1):67-99, viii
references.pmid: 18226731